



Cite this: *RSC Adv.*, 2019, 9, 9449

Biotransformation of 4-methylcoumarins by cambial meristematic cells of *Camptotheca acuminata*†

Yuhua Zhang, Jiayi Jiang, Ningbo Qin, Qian Zhang and Chunyan Yan *

Cambial meristematic cell (CMC) suspension cultures were investigated as a new biotransformation system for the first time. Four 4-methylcoumarins substrates were transformed by CMCs of *Camptotheca acuminata* into four corresponding products, including 4,8-dimethylcoumarin-7-*O*- β -D-glucopyranoside (I-1), 4,7-dimethylcoumarin-6-*O*- β -D-glucopyranoside (II-1), 6-hydroxy-7-methoxy-4-methylcoumarin (III-1), and 4,7-dimethylcoumarin-5-*O*- β -D-glucopyranoside (IV-1), of which I-1, II-1, and IV-1 were new compounds. In addition, the biotransformation time and the amount of substrate were investigated to compare the biotransformation rate and optimize the biotransformation conditions of the four substrates in *C. acuminata* CMCs suspension cultures. The results suggested *C. acuminata* CMCs were able to select glycosylate phenolic hydroxyl groups of 4-methylcoumarins I, II, and IV, with high regio- and stereoselectivity, but no corresponding glycoside of any phenolic hydroxyl group of compound III was detected. Simultaneously, the result also showed that the *C. acuminata* CMCs were able to transform the 7-hydroxy groups of substrate III to its corresponding methylated products. Furthermore, the monoamine oxidase (MAO) inhibition activities of biotransformed products were evaluated, and the data showed that all the products possessed good MAO inhibition activities *in vitro*. In conclusion, *C. acuminata* CMCs could be applied to glycosylation biotransformation as a novel plant-based system due to the successful application of bioconversion of exogenous coumarins.

Received 21st January 2019

Accepted 18th March 2019

DOI: 10.1039/c9ra00522f

rsc.li/rsc-advances

Introduction

Monoamine oxidase (MAO) is an iron-containing enzyme that is abundant in noradrenergic nerve terminals and often involved in the degradation of biogenic amines.¹ MAO is very important for the metabolism of several neurotransmitters and plays a significant role in the treatment of a number of psychiatric and neurological diseases, such as Parkinson's and Alzheimer's diseases.^{2,3} Coumarins are a large family of natural compounds and have a wide range of pharmacological activities, such as antitumor, antinociceptive, anticoagulant, anti-inflammatory, antimicrobial, antiviral, antioxidant, and antidepressant activities.⁴ Recently, coumarin and its derivatives have been employed as MAO inhibitors.^{5–8} However, the pharmaceutical and clinical application of coumarins is restricted by their low water solubility. Coumarin glycosides have higher water solubility and are easily transported in biological systems and play important roles in pharmaceutical and clinical applications as target drugs. Glycosylation of coumarins by chemical methods has several limitations, including tedious process, poor regio-

or stereoselectivity, low yields, and serious environmental pollution.⁹ Nevertheless, coumarin glycosides could be obtained *via* efficient, mild, and regio- or stereoselective biotransformation of coumarins in plant cells.¹⁰

Biotransformation catalyzed by biocatalysts, including enzymes, whole cells, or microorganisms, is widely used for biological structural modification with regio- and stereoselectivity, and this process has great potential to generate soluble and non-toxic metabolites *via* mild reaction conditions and fewer steps.^{11–14} Several studies on the bioconversion of coumarins in plant cells have been reported. Nine hydroxycoumarins with different substituted groups were biotransformed to investigate the substrate specificity and regioselectivity of coumarin glycosyltransferases in the hairy roots of *Polygonum multiflorum*.¹⁰ Zhou *et al.* reported that kellerin, a sesquiterpene coumarin derivative, was transformed into nine novel coumarin derivatives *via* dehydration, dehydrogenation, hydroxylation, and reduction using the callus of *Angelica sinensis* (Oliv.) Diels.¹⁵ In addition, the studies about transformation of polyphenol has been reported. SchmöLzer *et al.* reported integrated biocatalytic process for the nature polyphenol *C*-glucoside nothofagin.¹⁶ Phloridzin were synthesised using *Malus domestica* glycosyltransferase in engineered *Pichia pastoris* GS115.¹⁷

School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China. E-mail: ycybridge@163.com; Fax: +86-20-39352052; Tel: +86-20-39352052

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c9ra00522f



Cambial meristematic cells (CMCs), also known as plant stem cells, are innately undifferentiated cambium cell lines located in the meristems of plants and possess unlimited proliferation characteristics.¹⁸ The performance of CMCs is far superior to that of dedifferentiated plant cells (DDCs) on the basis of faster growth rates, higher yields of secondary metabolites and lower variability.¹⁹ Moreover, CMC suspension cultures can exhibit stable growth rates and growth properties on an industrial scale.^{19,20} This may likely be attributed to strikingly greater tolerance to shear stress, which limits the growth of cells and reduces cell aggregation in stirred tanks or air-lift bioreactors. The presence of small, abundant vacuoles within each CMC facilitates this phenomenon.^{20,21} In our previous study, *C. acuminata* CMCs were induced for the first time. Furthermore, the up-regulation of *IPI*, *G10H*, *ASA1*, *TSB*, *TDC1*, *TDC2*, and *STR*, which encode the key enzymes in the biosynthesis pathway of terpenoid indole alkaloids, resulted in the higher accumulation of camptothecin (CPT) and 10-hydroxycamptothecin (HCPT) in *C. acuminata* CMCs than in *C. acuminata* DDCs.²² As a new plant culture, *Camptotheca acuminata* CMCs have not been studied as a biotransformation system to transform exogenous substrates. Therefore, we aimed to determine whether plant stem cells with higher enzymatic activity can be used for biotransformation.

In the present study, the biotransformation of 4-methylcoumarins by *C. acuminata* CMCs was reported for the first time. Our aim was to explore the potential of *C. acuminata* CMCs for biotransformation reactions and develop a new and sustainable system on biotransformation of active molecules by CMCs of plants. Meanwhile, MAO inhibitory activities of all biotransformed products were also evaluated. Furthermore, the biotransformation time and amount of substrates were optimized to increase the biotransformation efficiency.

Results and discussion

Structures of substrates

4-Methylcoumarins were synthesized by a simple and efficient protocol shown as Table 1.

7-Hydroxy-4,8-dimethylcoumarin (I). White solid, mp 263.8–265.3 °C. HR-ESI-MS m/z : $[M + H]^+$ 191.0703. ¹³C NMR (125 MHz, DMSO-*d*₆) δ_C : 160.5 (C-2), 111.7 (C-3), 153.8 (C-4), 123.1 (C-5), 110.7 (C-6), 158.9 (C-7), 109.9 (C-8), 152.8 (C-9), 112.0 (C-10), 18.2 (4-CH₃), 8.0 (8-CH₃).²³

6-Hydroxy-4,7-dimethylcoumarin (II). Yellow solid, mp 207.7–208.3 °C. HR-ESI-MS m/z : $[M + H]^+$ 191.0705. ¹³C NMR (125 MHz, DMSO-*d*₆) δ_C : 160.2 (C-2), 113.4 (C-3), 152.0 (C-4), 117.8 (C-5), 152.7 (C-6), 130.2 (C-7), 117.9 (C-8), 146.1 (C-9), 108.3 (C-10), 18.0 (4-CH₃), 16.2 (7-CH₃).²⁴

6,7-Dihydroxy-4-methylcoumarin (III). Yellow solid, mp 199.5–201.3 °C. HR-ESI-MS m/z : $[M + H]^+$ 193.0495. ¹³C NMR (125 MHz, DMSO-*d*₆) δ_C : 160.0 (C-2), 109.6 (C-3), 152.8 (C-4), 119.8 (C-5), 149.7 (C-6), 146.2 (C-7), 115.6 (C-8), 153.8 (C-9), 114.5 (C-10), 18.1 (4-CH₃).²⁵

5-Hydroxy-4,7-dimethylcoumarin (IV). White solid, mp 250.9–252.2 °C. HR-ESI-MS, m/z : $[M + H]^+$ 191.0704. ¹³C NMR (125 MHz, DMSO-*d*₆) δ_C : 159.8 (C-2), 107.7 (C-3), 154.6 (C-4),

156.4 (C-5), 111.9 (C-6), 142.8 (C-7), 111.9 (C-8), 154.9 (C-9), 106.5 (C-10), 23.5 (4-CH₃), 21.1 (7-CH₃).²⁶









Identification of transformed products

After HPLC analysis, it was seen that four products were formed, followed by the appearance of four additional peaks at retention time of 16.94 (**I-1**), 16.99 (**II-1**), 17.80 (**III-1**) and 22.19 (**IV-1**) min, respectively (Fig. 1). Then, four products from the biotransformation of 4-methylcoumarins with *C. acuminata* CMCs were identified.

Compound **I** was transformed to **I-1** in *C. acuminata* CMCs. **I-1** was obtained as a yellow solid, and its HR-ESI-MS spectrum showed a pseudo molecular ion peak at m/z 353.1234 $[M + H]^+$ (calcd 353.1231 for C₁₇H₂₁O₈), indicating a molecular formula of C₁₇H₂₀O₈. IR (KBr) ν_{\max} 3509, 2934, 1722, 1609, 1383, 1285, 1076 cm⁻¹. The ¹³C NMR spectrum showed carbon signals of δ_C 160.3, 158.0, 153.6, 152.0, 123.3, 114.1, 113.8, 111.6, 111.1, 18.2 and 8.3. The ¹H NMR spectrum showed proton signals of δ_H 7.57 (1H, d, $J = 8.3$ Hz), 7.15 (1H, d, $J = 8.3$ Hz) and 6.23 (1H, d, $J = 1.1$ Hz). The ¹³C, ¹H NMR and IR spectra indicated compound **I-1** was a coumarin similar with compound **I**. In addition, the additional proton signals of δ_H 4.96 (1H, d, $J = 7.2$ Hz, H-1'), 3.20–3.36 (4H, m, H-2'-5'), 3.69 (1H, d, $J = 11.4$ Hz, H-6'a), and 3.48 (1H, m, H-6'b) and carbon signals of δ_C 100.6, 77.2, 76.6, 73.3, 69.7, and 60.7 were observed in the ¹H NMR and ¹³C NMR spectra of compound **I-1** (Table 2), which suggested the presence of a glucopyranosyl moiety in **I-1**. Comparison of the ¹H and ¹³C NMR data with those of **I** revealed that compound **I-1** is a glucoside of **I** (Table 2).¹⁰ In the HMBC spectrum, the correlation of the anomeric proton signal at δ 4.96 (H-1') to the carbon signal at δ 158.0 (C-7) indicated that the sugar was linked to C-7. The ¹³C NMR chemical shift of the anomeric carbon, along with the ¹H NMR chemical shift and spin-spin coupling constant ($J = 7.2$ Hz) of the anomeric proton, allowed for the identification of a β -glucopyranosyl moiety. Based on these data, the structure of compound **I-1** was identified as 4,8-dimethylcoumarin-7-*O*- β -D-glucopyranoside, which is a new compound.

Compound **II** was biotransformed by *C. acuminata* CMCs to a new compound, namely compound **II-1**. Compound **II-1** was obtained as a pale solid, with a molecular formula of C₁₇H₂₀O₈ based on a pseudo-molecular ion peak at m/z 353.1235 $[M + H]^+$ (calcd 353.1231 for C₁₇H₂₁O₈) in HR-ESI-MS. IR (KBr) ν_{\max} 3365, 2830, 1644, 1624, 1385, 1028 cm⁻¹. The ¹H NMR and ¹³C NMR data of compound **II-1** exhibited an additional glucopyranosyl moiety at δ_H 4.87 (1H, d, $J = 7.4$ Hz, H-1'), 3.14–3.31 (3H, m, H-2'-4'), 3.44 (2H, m, H-5', 6'a), and 3.74 (1H, dd, $J = 11.4, 4.1$ Hz, H-6'b) and δ_C 101.5, 77.4, 76.8, 73.3, 70.2, 61.0. Comparison of the ¹H and ¹³C NMR data with those of **II** revealed that compound **II-1** is a glucoside of **II** (Table 2).²⁷ In the HMBC spectrum, the correlation of the anomeric proton signal at δ_H 4.87 (H-1') to the carbon signal at δ_C 152.1 (C-6) indicated that the sugar was linked to C-6. The β -anomer of the glucose was determined by the anomeric carbon at δ_C 101.5, anomeric proton at δ_H 4.87, and coupling constant (7.4 Hz). Therefore, the structure of compound **II-1** was assigned as 4,7-dimethylcoumarin-6-*O*- β -D-glucopyranoside.

Table 1 Synthesis of four substrates

| Reactant | Temperature (°C) | Time (min) | Product |
|---|------------------|------------|---|
|  | 90 | 45 |  |
|  | 95 | 20 |  |
|  | 110 | 30 |  |
|  | 90 | 25 |  |

Compound **III-1**, a yellow crystal (MeOH), gave a molecular formula of $C_{11}H_{10}O_4$ by HR-ESI-MS at m/z 207.0650 $[M + H]^+$ (calcd 207.0652 for $C_{11}H_{11}O_4$). The structure of **III-1** was determined as 6-hydroxy-7-methoxy-4-methylcoumarin based on the comparison of the NMR spectra with known compound.²⁸

Compound **IV-1**, a pale solid, was assigned the molecular formula $C_{17}H_{20}O_8$ on the basis of its HR-ESI-MS data at m/z 353.1223 $[M + H]^+$ (calcd 353.1231 for $C_{17}H_{21}O_8$). IR (KBr) ν_{max} 3339, 2945, 1718, 1695, 1607, 1386, 1074, 1031 cm^{-1} . The 1H and ^{13}C NMR spectra of compound **IV-1** were similar to that of compound **IV**, and the major differences were the presence of signals for a sugar residue, namely δ_H 4.99 (1H, d, $J = 7.2$ Hz, H-1'), 3.32 (2H, m, H-2'-3'), 3.19 (1H, t, $J = 8.6$ Hz, H-4'), 3.38 (1H, m, H-5'), and 3.70 (1H, d, $J = 11.4$ Hz, H-6') and δ_C 101.1, 77.2, 76.9, 73.4, 69.7, 60.6. The HMBC correlation of δ_H 4.99 (H-1') to the carbon signal at δ_C 155.7 (C-5) suggested that the sugar unit was linked to C-5. The relative configuration of the glucose residue was deduced to β on the basis of the coupling constant (7.2 Hz) and the anomeric carbon at δ_C 101.1. Thus, compound **IV-1** was defined structurally as 4,7-dimethylcoumarin-5-O- β -D-glucopyranoside, and this is a new compound (Table 2).

Effects of time course on 4-methylcoumarins biotransformation

The biotransformation properties of 4-methylcoumarins by *C. acuminata* CMCs were evaluated and compared by time course

experiments after incubation for 1, 2, 3, 4, 5, 6, or 7 d, respectively. The co-culture time was different, according to the distinct target product during the biotransformation process by CMCs. As shown in Fig. 2, the biotransformation ratio of compound **I** significantly increased from 1–2 d and increased slightly from 2–7 d. In addition, CMCs produced the highest biotransformation rate of 3.59% after co-culture for 7 d. Thus, the optimum incubation time of **I** was 7 d in *C. acuminata* CMCs. The bioconversion ratio of compounds **II** to **II-1** declined from 1 to 2 d, significantly increased from 2 to 5 d, and decreased again after 6 d in CMCs. This may be due to the feedback of the products in the culture. The maximum bioconversion ratio from compounds **II** to **II-1** was 9.89% in CMCs. Therefore, the optimal co-culture time of **II** was 5 d in *C. acuminata* CMCs. The biotransformation ratio of **III** fluctuated slightly over the entire incubation period, and the maximum biotransformation ratio was 1.27% at 6 d in CMCs. The biotransformation ratio of **IV** significantly increased until the 4th day of culture. Therefore, the optimal incubation time of **IV** was 4 d, with a maximum biotransformation rate of 6.32% in CMCs.

Effect of substrate amount on the 4-methylcoumarins biotransformation

The effects of different amounts of substrates on biotransformation were investigated in *C. acuminata* CMCs (Fig. 3). The




Fig. 1 HPLC chromatograms of biotransformation of (A) 7-hydroxy-4,8-dimethylcoumarin (I), (B) 6-hydroxy-4,7-dimethylcoumarin (II), (C) 6,7-dihydroxy-4-methylcoumarin (III), (D) 5-hydroxy-4,7-dimethylcoumarin (IV). Substrates I, II, III and IV could be transformed into I-1, II-1, III-1 and IV-1 by *C. acuminata* CMCs, respectively.

yield of I-1 was 6.90% when 8 mg of I was added to the CMCs. The yield of I-1 sharply declined as the concentration of I in CMCs increased. There was no obvious change in the yield of II-1 with increasing concentration of II, and the highest yield was 1.41% when 14 mg of II were added. The yield of III-1 fluctuated slightly, and the maximum yield was 0.61% when 10 mg III were added to the CMCs. The yield of IV-1 gradually decreased with increasing concentration of IV, and the highest yield was 10.10% when 8 mg of IV were added to the CMCs.

Inhibition of MAO activity assay

The MAO inhibition activities of all biotransformed products were evaluated *in vitro* using an MAO kit. As shown in Fig. 4, all products possessed good MAO inhibition activities, and the MAO inhibition activities of the four products slowly declined with increasing concentration of the tested products. Compound I-1 showed the best MAO inhibition activity.

Based on the structures of four products, we supposed that compound I, II and IV were transformed into I-1, II-1 and IV-1 by glycosylation, respectively, and compound III was transformed into III-1 by methylation (Fig. 5). The results from the biotransformation studies indicated that glycosylation of

phenol hydroxyl groups of the three 4-methylcoumarins *via C. acuminata* CMCs was stereoselective and led to the formation of corresponding β -D-glucopyranosides. We speculated that compound III, with two phenolic hydroxyl groups, could be selectively methylated rather than glycosylated by the *C. acuminata* CMCs, which was very different from the *P. multiflorum* hairy root cultures.¹⁰ Moreover, the methylation conversion was regioselective at position C-7.

CMCs are innately undifferentiated cells located in the meristems of plants and can yield more natural products than DDCs.^{22,29} CMCs induced by our group from *C. acuminata* were reported to be a better source of the anticancer drug camptothecin and its derivatives.²² Now, we report that *C. acuminata* CMCs also transform some exogenous substrates to their corresponding water-soluble and low-toxic derivative; therefore, *C. acuminata* CMCs could be used as a new transformation culture.



Materials and methods

General experimental procedures

1D and 2D- nuclear magnetic resonance spectroscopy (NMR) spectra were recorded on Bruker ARX-500 and ARX-600

Table 2 ^1H (500 MHz) and ^{13}C NMR (125 MHz) data for biotransformed products I-1, II-1 and IV-1 in $\text{DMSO}-d_6$

| Position | I-1 | | II-1 | | IV-1 | |
|------------------|-----------------------|--------------------------------------|-----------------------|--------------------------------------|-----------------------|--------------------------------------|
| | $\delta^{13}\text{C}$ | $\delta^1\text{H}$ (mult, J in Hz) | $\delta^{13}\text{C}$ | $\delta^1\text{H}$ (mult, J in Hz) | $\delta^{13}\text{C}$ | $\delta^1\text{H}$ (mult, J in Hz) |
| 2 | 160.3 | | 160.2 | | 159.6 | |
| 3 | 111.6 | 6.23 (d, 1.1) | 113.5 | 6.30 (d, 0.8) | 113.3 | 6.14 (d, 1.0) |
| 4 | 153.6 | | 153.4 | | 154.3 | |
| 5 | 123.3 | 7.57 (d, 8.3) | 110.3 | 7.38 (s) | 155.7 | |
| 6 | 111.1 | 7.15 (d, 8.3) | 152.1 | | 111.4 | 6.85 (s) |
| 7 | 158.0 | | 132.8 | | 143.2 | |
| 8 | 113.8 | | 117.7 | 7.22 (s) | 110.6 | 6.92 (s) |
| 9 | 152.0 | | 147.9 | | 154.4 | |
| 10 | 114.1 | | 117.9 | | 108.1 | |
| 4- CH_3 | 18.2 | 2.39 (d, 1.1) | 18.1 | 2.39 (d, 0.8) | 23.9 | 2.60 (s) |
| 7- CH_3 | | | 16.3 | 2.30 (s) | 21.5 | 2.35 (s) |
| 8- CH_3 | 8.3 | 2.24 (s) | | | | |
| | | Glc | | Glc | | Glc |
| 1' | 100.6 | 4.96 (d, 7.2) | 101.5 | 4.87 (d, 7.4) | 101.1 | 4.99 (d, 7.2) |
| 2' | 73.3 | 3.31 (m) | 73.3 | 3.31 (m) | 73.4 | 3.32 (m) |
| 3' | 76.6 | 3.31 (m) | 76.8 | 3.31 (m) | 76.9 | 3.32 (m) |
| 4' | 69.7 | 3.20 (m) | 70.2 | 3.14 (m) | 69.7 | 3.19 (t, 8.6) |
| 5' | 77.2 | 3.36 (m) | 77.4 | 3.44 (m) | 77.2 | 3.38 (m) |
| 6' | 60.7 | 3.69 (d, 11.4) | 61.0 | 3.74 (dd, 11.4, 4.1) | 60.6 | 3.70 (d, 11.4) |
| | | 3.48 (m) | | 3.44 (m) | | 3.49 (m) |
| Sugar-OH | | 5.44 (br s) | | 5.39 (br s) | | 5.43 (br s) |
| Sugar-OH | | 5.18 (br s) | | 5.17 (br s) | | 5.27 (br s) |
| Sugar-OH | | 5.11 (br s) | | 5.11 (br s) | | 5.18 (br s) |
| Sugar-OH | | 4.60 (br s) | | 4.70 (t, 5.3) | | 4.68 (br s) |

Fig. 2 Time course of the biotransformation of four substrates by *C. acuminata* CMCs. The product yield is expressed as a percentage relative to the total amount of reaction products.Fig. 3 The effect of substrate amount on product yield in the biotransformation of *C. acuminata* CMCs. The yield of products is expressed as a percentage relative to the total amount of reaction products.

spectrometers with tetramethylsilane (TMS) as an internal standard. High-resolution electrospray ionization mass spectroscopy (HR-ESI-MS) was employed on a Shimadzu LCMS-IT-TOF (Kyoto, Japan). 2-Methyl resorcinol, 2-methyl hydroquinone, 5-methyl resorcinol, 1,2,4-benzenetriol, and phosphotungstic acid ($\text{H}_3\text{PW}_{12}\text{O}_{40}$) were purchased from Aladdin Industrial Corporation (Shanghai, China). The melting point was obtained on a micro-melting point apparatus (X-6, Tektronix, USA). An HPLC (1260 system, Agilent, USA) system equipped with a C_{18} column (250 \times 4.6 mm, 5 μm ; Phenomenex Synergi, USA) was used, and a semi-preparative RP-HPLC

method was conducted with a C_{18} column (250 \times 10 mm, 5 μm ; YMC Co., Ltd.). The rat liver was homogenized by a homogenizer (T10, IKA, Germany), and the mitochondria were isolated on a high-speed freezing centrifuge (TGL 20br, Anting, Shanghai, China). Phosphate buffer saline (PBS, pH 7.4), used to isolate the rat liver, was purchased from Haibiao Technology Company (Xiamen, China). A monoamine oxidase assay kit was purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). A Bradford protein quantitation assay kit was purchased from KeyGEN Biotechnology Company (Nanjing, China).




Fig. 4 MAO inhibitory activity of biotransformed products. Values were expressed as means \pm SD ($n = 3$).

Synthesis of substrates

A mixture of substituted phenol (5 mmol), ethyl acetate (6 mmol), and phosphotungstic acid (0.5 mmol) in toluene (5 mL) was stirred for 45 min at 90–110 °C under reflux conditions (Table 1). Then, the mixture was dissolved in 75% ethanol and filtered immediately. The pure crystals of the products were obtained from the filtrate by recrystallization.

Culture system and biotransformation procedures

CMCs were induced from stems of *C. acuminata* and identified successfully in our research group previously, and B₅ medium was determined as the best growth medium.²² CMCs were cultured in liquid B₅ medium supplemented with 1.0 mg L⁻¹ naphthalene-acetic acid (NAA), 0.5 mg L⁻¹ 2,4-dichlorophenoxyacetic (2,4-D), 0.05 mg L⁻¹ kinetin (KT), and 30 g L⁻¹ sucrose. The pH of the liquid medium was adjusted to 5.75, and the medium was sterilized at 120 °C for 20 min. Four grams of CMCs (fresh weight) were cultured in a 250 mL Erlenmeyer flask with 100 mL of the supplemented B₅ medium, and the cultures were incubated at 25 °C \pm 1 °C for 7 d on a rotatory shaker (110 rpm). Eight milligrams of substrates were dissolved in DMSO at a final concentration of 20 mg mL⁻¹ and were added to the above suspension cultures, respectively. The cultures were incubated for another 7 d. Culture control groups consisted of equal amounts of cultures, medium and DMSO without substrates. Substrate control groups consisted of an equal amount of DMSO, substrate, and medium in the absence of cultures. A total of 220 mg of each substrate were added to 27 bottles of suspension cultures to prepare the biotransformation products on a preparative scale.




Fig. 5 Possible biotransformation pathways of four substrates in *C. acuminata* CMCs.

Extraction, isolation and purification of biotransformation products

After a 7 d incubation, the cultures and medium were separated by filtration. The medium was extracted three times with equal volumes of ethyl acetate (EtOAc) and *n*-butyl alcohol (*n*-BuOH), respectively. The cultures were dried at 55 °C and extracted with methanol (MeOH) three times. All extracts were evaporated to dryness and analyzed by HPLC. The EtOAc and MeOH extracts were combined and subjected to silica gel column chromatography with a gradient mixture of petroleum ether and EtOAc (50 : 1, 30 : 1, 20 : 1, 15 : 1, 8 : 1, 2 : 1, 1 : 1) as the eluent. The eluate was further purified by RP-HPLC to afford four biotransformation products. The structures of the biotransformed products were established *via* chemical and spectroscopic methods.

Optimization studies

Biotransformation time. In order to improve the conversion ratio of substrates, the optimal incubation time was evaluated. Four grams of *C. acuminata* CMCs (fresh weight) were cultured in a 250 mL Erlenmeyer flask with 100 mL medium and mixed *via* rotatory shaker (110 rpm) for 7 d at 25 °C ± 1 °C. Eight milligrams of substrates dissolved in DMSO were added to above suspension cultures and incubated for 1, 2, 3, 4, 5, 6, or 7 d, respectively. The mixtures were analyzed by an HPLC equipped with an ultraviolet detector at 210 nm. The mobile phases were MeOH and 0.1% trifluoroacetic acid (TFA) and were programmed as follows: a linear gradient from 30 : 70 (v/v) to 75 : 25 (v/v) in 20 min, followed by a linear gradient from 75 : 25 (v/v) to 30 : 70 (v/v) in 5 min, and finally a gradient of 30 : 70 (v/v) in 10 min. The flow rate was 1.0 mL min⁻¹, and the column temperature was 25 °C.

Substrates concentrations. The transformation ratio of substrates was determined for different amounts of substrate. First, 4 grams of *C. acuminata* CMCs (fresh weight) were cultured in a 250 mL Erlenmeyer flask containing 100 mL of medium, and the cultures were incubated at 25 °C ± 1 °C for 7 d on a rotatory shaker (110 rpm). Next, 8, 10, 12, or 14 mg of substrates dissolved in DMSO were administered to above suspension cultures, respectively. The cultures were then incubated for 7 d. The mixtures were analyzed by HPLC as described above.

Monoamine oxidase inhibiting activity tests

Isolation of mitochondria. Mitochondria were isolated from a rat liver, according to a previously reported method with slight modifications.^{30,31} A female SD rat (220 g) was purchased from Guangzhou University of Chinese Medicine Animal Experimentation Center (Certificate: SCXK2013-0020) and euthanized. The liver was quickly excised and rinsed with PBS (pH 7.4). Two grams of liver tissue were minced with scissors and placed into a tube containing 80 mL of 0.3 M sucrose. The mixture was transferred into a homogenizer and homogenized for 2 min. The liver homogenate was centrifuged at 1000g for 10 min, and then the supernatant was further centrifuged at 10 000g for

30 min at 4 °C to obtain the mitochondrial precipitate. The precipitate was rinsed with PBS (pH 7.4), and then suspended in 20 mL of PBS (pH 7.4). The mitochondria protein concentration was measured *via* Bradford protein quantitation assay.³² The standard curve of protein was obtained as $Y = 0.026X - 0.0402$ ($R^2 = 0.9999$), where Y indicates the absorbance at 595 nm, and X indicates the concentration of protein.

Monoamine oxidase inhibitory activity assay. Bio-transformed products were dissolved in DMSO to a concentration of 200 mg L⁻¹, and their MAO inhibitory activities at final concentrations of 5 mg L⁻¹, 10 mg L⁻¹, 20 mg L⁻¹, 50 mg L⁻¹ and 100 mg L⁻¹ were evaluated using a monoamine oxidase assay kit.

Conclusion

The biotransformation of 4-methylcoumarins was carried out by *C. acuminata* CMCs for the first time, and four products, including three new compounds, were produced. The biotransformation time and the amount of substrate were optimized to obtain high yields. Furthermore, MAO inhibition activities of transformed products were evaluated. In conclusion, the CMCs could be used as a promising biotransformation system, which has immense potential to produce biologically active compounds by glycosylation. The enzymes catalyzed the transformed reactions in *C. acuminata* CMCs with high regio- and stereoselectivity. The characterization of enzymes that catalyzed the glycosylation and methylation of coumarins is now in progress.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This study was funded by the National Natural Science Foundation of China (No. 81102779), the Guangdong Natural Science Foundation (No. 9451022401003453) and the Innovative and Upgrading Schools Project of Guangdong Province (No. 2017KZDXM048).

References

- 1 K. Chen, D. P. Holschneider, W. H. Wu, I. Rebrin and J. C. Shih, *J. Biol. Chem.*, 2004, **279**, 39645–39652.
- 2 H. H. Fernandez and J. J. Chen, *Clin. Neuropharmacol.*, 2007, **30**, 150–168.
- 3 P. Riederer, W. Danielczyk and E. Grunblatt, *Neurotoxicology*, 2004, **25**, 271–277.
- 4 P. O. Patil, S. B. Bari, S. D. Firke, P. K. Deshmukh, S. T. Donda and D. A. Patil, *Bioorg. Med. Chem.*, 2013, **21**, 2434–2450.
- 5 A. Fonseca, M. J. Matos, J. Reis, Y. Duarte, M. Gutiérrez, L. Santana, E. Uriarte and F. Borges, *RSC Adv.*, 2016, **6**, 49764–49768.
- 6 M. J. Matos, S. Vazquez-Rodriguez, E. Uriarte, L. Santana and D. Viña, *Bioorg. Med. Chem.*, 2011, **21**, 4224–4227.

- 7 S. Serra, G. Ferino, M. J. Matos, S. Vázquezrodríguez, G. Delogu, D. Viña, E. Cadoni, L. Santana and E. Uriarte, *Bioorg. Med. Chem.*, 2012, **22**, 258–261.
- 8 D. Viña, M. J. Matos, M. Yáñez, L. Santana and E. Uriarte, *Med. Chem. Commun.*, 2012, **3**, 213–218.
- 9 D. Chen, R. Chen, K. Xie, T. Yue, X. Zhang, F. Ye and J. Dai, *Org. Lett.*, 2018, **20**, 1634–1637.
- 10 L. Zhou, T. Tian, B. Xue, L. Song, L. Liu and R. Yu, *Biosci., Biotechnol., Biochem.*, 2012, **76**, 1008–1010.
- 11 T. I. Kylosova, A. A. Elkin, V. V. Grishko and I. B. Ivshina, *J. Mol. Catal. B: Enzym.*, 2016, **123**, 8–13.
- 12 S. G. Musharraf, J. Uddin, M. Akhter, M. Parvez, Saifullah, S. Khan, S. Yousuf, S. Khan and M. I. Choudhary, *J. Mol. Catal. B: Enzym.*, 2012, **82**, 80–85.
- 13 M. Y. Rather, S. Mishra, V. Verma and S. Chand, *Bioresour. Technol.*, 2012, **107**, 287–294.
- 14 X. L. Xin, G.-J. Fan, Z. Sun, N. Zhang, Y. Li, R. Lan, L. Chen and P. P. Dong, *J. Mol. Catal. B: Enzym.*, 2015, **122**, 141–146.
- 15 D. Zhou, N. Li, Y. H. Zhang, C. Y. Yan, K. Jiao, Y. Sun, H. Ni, B. Lin and Y. Hou, *RSC Adv.*, 2016, **6**, 97302–97312.
- 16 K. Schmölzer, M. Lemmerer and B. Nidetzky, *Biotechnol. Bioeng.*, 2018, **115**, 545–556.
- 17 T.-J. Zhang, J.-Q. Liang, X.-Y. Wei, P.-X. Wang, Y. Wu, S. Pen and M.-T. Fan, *Process Biochem.*, 2017, **59**, 187–193.
- 18 Z. H. Ye, *Annu. Rev. Plant Biol.*, 2002, **53**, 183–202.
- 19 E.-K. Lee, Y.-W. Jin, J. H. Park, Y. M. Yoo, S. M. Hong, R. Amir, Z. Yan, E. Kwon, A. Elfick, S. Tomlinson, F. Halbritter, T. Waibel, B.-W. Yun and G. J. Loake, *Nat. Biotechnol.*, 2010, **28**, 1213–1217.
- 20 B.-W. Yun, Z. Yan, R. Amir, S. Hong, Y.-W. Jin, E.-K. Lee and G. J. Loake, *Biotechnol. Genet. Eng. Rev.*, 2012, **28**, 47–60.
- 21 J. B. Joshi, C. B. Elias and M. S. Patole, *Chem. Eng. J.*, 1996, **62**, 121–141.
- 22 Y. H. Zhang, K. M. Jiang, D. G. Qing, B. Huang, J. Y. Jiang, S. M. Wang and C. Y. Yan, *RSC Adv.*, 2017, **7**, 12185–12193.
- 23 R. S. Keri, K. M. Hosamani and H. R. Seetharama Reddy, *Catal. Lett.*, 2009, **131**, 321–327.
- 24 M. M. Heravi, M. Khorasani, F. Derikvand, H. A. Oskooie and F. F. Bamoharram, *Catal. Commun.*, 2007, **8**, 1886–1890.
- 25 J.-X. Yu, P. K. Gulaka, L. Liu, V. D. Kodibagkar and R. P. Mason, *ChemPlusChem*, 2012, **77**, 370–378.
- 26 L. Moradi and F. Belali, *J. Iran. Chem. Soc.*, 2015, **12**, 1927–1934.
- 27 X. B. Yang, J. Hou, D. Liu, S. Deng, Z. B. Wang, H. X. Kuang, C. Y. Wang, J. H. Yao, K. X. Liu and X. C. Ma, *J. Mol. Catal. B: Enzym.*, 2013, **88**, 1–6.
- 28 J. K. OH, V. Stöeva, J. Rademacher, R. Farwaha and M. A. Winnik, *J. Polym. Sci., Part A: Polym. Chem.*, 2004, **42**, 3479–3489.
- 29 N. Ding, Z. Xu, B. Huang, L. Han, S. Li and C. Yan, *J. Pharm. Sci. Innovation*, 2015, **4**, 33–35.
- 30 S. M. Korotkov, I. V. Brailovskaya, A. R. Shumakov and L. V. Emelyanova, *J. Bioenerg. Biomembr.*, 2015, **47**, 243–254.
- 31 G. I. Stafford, P. D. Pedersen, A. K. Jäger and J. V. Staden, *S. Afr. J. Bot.*, 2007, **73**, 384–390.
- 32 M. M. Bradford, *Anal. Biochem.*, 1976, **72**, 248–254.